obesity 4 - Medxy AI

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

By MedXY 08/02/2025

Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.

Diabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

Medical News news Oncology Specialties

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise

By MedXY 07/31/2025

Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.

Cardiology Diabetes & Endocrinology Medical News news Specialties

Redefining Obesity: Impact of the ‘Clinical Obesity’ Framework on Global Prevalence Estimates

By MedXY 07/30/2025

A new, function-driven definition of “clinical obesity” dramatically lowers global obesity prevalence rates compared to BMI-based estimates, raising implications for disease surveillance, prevention, and healthcare policy.

Cardiology Diabetes & Endocrinology news Specialties

Understanding Macronutrients: Their Role in Obesity and Weight Management

By MedXY 07/29/2025

Explore the impact of macronutrients on obesity, focusing on carbohydrates, proteins, and fats, and learn strategies for effective weight management.

Diabetes & Endocrinology news Specialties

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

By MedXY 07/28/2025

Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.

news

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

By MedXY 07/28/2025

Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.

Diabetes & Endocrinology news

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.

Diabetes & Endocrinology news Specialties

Unraveling the Gut-Brain Connection: How Our Brain Detects Glucose

By MedXY 07/25/2025

Scientists at KAIST have identified a unique gut-brain pathway that enables the brain to distinguish glucose from other nutrients, paving the way for novel treatments for metabolic disorders.

Diabetes & Endocrinology Infectious Diseases news

Impact of Obesity on Long COVID: Insights from Primate Studies

By MedXY 07/25/2025

Obesity influences the long-term effects of SARS-CoV-2, revealing diverse outcomes in primates and suggesting broader implications for humans.